PRESS RELEASE
20 September 2018

BioInvent's partner Oxurion enrolls first patient in phase 2 clinical study evaluating THR-317 for treatment of idiopathic MacTel 1

Lund, Sweden – 20 September 2018 – BioInvent International AB's (OMXS: BINV) partner Oxurion (formerly known as ThromboGenics) reports today that it has enrolled the first patient in a phase 2 open-label multi-centre study evaluating the efficacy and safety of intravitreal THR-317, an anti-PIGF (human placental growth factor) antibody, for the treatment of Macular Telangiectasia Type 1 (MacTel 1).

MacTel 1 is a rare disease that affects the macula and can lead to vision loss. There is currently no cure or effective treatment for MacTel 1. This Phase 2 study (THR-317-003 - *NCT03669393*) plans to enrol 10 patients with macular edema caused by MacTel 1.

In 2017, Oxurion gained full and exclusive ownership of THR-317 for development and commercialization in all non-oncology indications. In exchange, BioInvent is entitled to five percent of the program's economic value.

For further information, see Oxurion's press release of 20 September 2018 (www.oxurion.com).

About BioInvent
BioInvent International AB (OMXS: BINV) is focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies to treat cancer. The Company's lead program is BI-1206, currently in a Phase 1/2 for non-Hodgkin lymphoma and chronic lymphatic leukaemia. BioInvent's pre-clinical portfolio is focused on targeting key immune suppressive cells and pathways of the tumor microenvironment, including regulatory T cells, tumor-associated myeloid cells and mechanisms of antibody drug-resistance. The Company has a strategic research collaboration with Pfizer Inc., and partnerships with Transgene, Bayer Pharma, Daiichi Sankyo, and Mitsubishi Tanabe Pharma. BioInvent generates near term revenues from its fully integrated manufacturing unit producing antibodies for third parties for research through to late-stage clinical trials. More information is available at www.bioinvent.se

For further information, please contact:

Martin Welschof, CEO
+46 (0)46 286 85 50
martin.welschof@bioinvent.com

Hans Herklots, LifeSci Advisors
+41 79 598 71 49
hherklots@lifesciadvisors.com

BioInvent International AB (publ)
Co. reg. No. 556537-7263
Visiting address: Sölvegatan 41
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.se

The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

This information is information that BioInvent International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 7.30 a.m. CET, on 20 September, 2018.